Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1063867
  • May 2021
  • Pharmaceuticals
  • 119 Pages
The Human Immunodeficiency Virus (HIV)-1 Therapeutics market research report provides an in-depth analysis of the currents trends, latest developments, scenario, market size, various drivers, restraints, and major players along with their profile details. Research report offers the historic data for year 2018 and 2019 and also provides the forecast data from year 2020 to 2028 which is based on revenue (USD Million). With the help of all these information research report helps the market participants to improve market positions. With the help of all these insights Human Immunodeficiency Virus (HIV)-1 Therapeutics market research report recommends a business strategy for present market participants to strengthen their position in the market.
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2020
Forecast Period Covered 2020 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Companies Covered Gilead Sciences, Inc, ViiV Healthcare, AbbVie, Inc, Merck and Co., Inc, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Genentech, Inc, Cipla,Inc, janssen Pharmaceutica, Johnson and Johnson
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

COVID-19 Impact Analysis
The analysis of covid-19 is based on the impact of the current pandemic situation on market scenarios. This includes impact of covid-19 outbreak on overall revenue, market segments as well as regional market. The report also puts light on detailed impact analysis by taking into consideration all the government policies imposed during the pandemic situation, temporary shutdown of manufacturing units, current state of supply chain and distributors, and its future impacts on the growth of overall market. The market study will assist user to understand the global demand and impose strategic business plans to compete with the peers.

Furthermore, the research report includes the detailed information about major players and provides the data regarding the current market scenario as well as upcoming market opportunities or challenges. Similarly, in segment report covers the types, and applications according to the countries and key regions. The research report consists the various drivers and restraints for Human Immunodeficiency Virus (HIV)-1 Therapeutics market along with their effects over the forecast period. Similarly, according to the region Human Immunodeficiency Virus (HIV)-1 Therapeutics market research report includes the study of opportunities available in the market situation.

The Human Immunodeficiency Virus (HIV)-1 Therapeutics market research report provides the in-depth data analysis by using the various graphs, figures, charts, and tables. Furthermore, the report provides the different business challenges which are impacting market growth in all direction.

Major Key Players for Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market:
The Human Immunodeficiency Virus (HIV)-1 Therapeutics market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. Gilead Sciences, Inc, ViiV Healthcare, AbbVie, Inc, Merck and Co., Inc, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Genentech, Inc, Cipla,Inc, janssen Pharmaceutica, Johnson and Johnson

Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Segmentation Analysis:
By Drug Class
Nucleoside-Analog Reverse Transcriptase Inhibitors
NRTIs
Non-Nucleoside Reverse Transcriptase Inhibitors
NNRTIs
Entry and Fusion Inhibitors
Protease Inhibitors
PIs
Integrase Inhibitors
Coreceptor Antagonists
Application
Hospital
Clinics
Others

Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Segmentation by Regions:
In regional analysis, Human Immunodeficiency Virus (HIV)-1 Therapeutics market research report provides the detailed analysis from various regions and also contains the detailed analysis of country. Along with market revenue, market value report also offers the forecast analysis for the following countries and regions. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics market report covers the various geographical regions such as North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa. Also, various countries included are Canada, U.K., France, the U.S., Japan, China, India, and Germany and so on.

North America Region for Human Immunodeficiency Virus (HIV)-1 Therapeutics Market: Value and Forecast
  • U.S.
  • Canada
 Europe Region for Human Immunodeficiency Virus (HIV)-1 Therapeutics Market: Value and Forecast
  • UK
  • Germany
  • France
  • Rest of the Europe
 Asia Pacific Region for Human Immunodeficiency Virus (HIV)-1 Therapeutics Market: Value and Forecast
  • China
  • Japan
  • India
  • Rest of the Asia Pacific
 Latin America Region for Human Immunodeficiency Virus (HIV)-1 Therapeutics Market: Value and Forecast
  • Mexico
  • Brazil
  • Rest of the Latin America
 Middle East and Africa for Human Immunodeficiency Virus (HIV)-1 Therapeutics Market: Value and Forecast
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa


Important Points Covered by Report:
  • To analyze the value of the Human Immunodeficiency Virus (HIV)-1 Therapeutics market, according to the key region.
  • To study the Human Immunodeficiency Virus (HIV)-1 Therapeutics market current trends, prospects and also their participation in the entire sector.
  • Report consists the in-depth information related to the region/countries, major key players, current trends and their analysis, product type, applications, and other background information
  • Report provides the detailed information about drivers, restraints and future scope of Human Immunodeficiency Virus (HIV)-1 Therapeutics market.
  • Report covers the information about historic data analysis as well as forecast period analysis.

Global Human Immunodeficiency Virus (HIV)-1 Therapeutics research report consist the information about overall sales and revenue during the historic and forecasted period of 2018 to 2028. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Human Immunodeficiency Virus (HIV)-1 Therapeutics market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Human Immunodeficiency Virus (HIV)-1 Therapeutics market for numerous purposes such as:

    1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Human Immunodeficiency Virus (HIV)-1 Therapeutics market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Human Immunodeficiency Virus (HIV)-1 Therapeutics market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Human Immunodeficiency Virus (HIV)-1 Therapeutics market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

  • Gilead Sciences, Inc
  • ViiV Healthcare
  • AbbVie, Inc
  • Merck and Co., Inc
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim GmbH
  • Genentech, Inc
  • Cipla,Inc
  • janssen Pharmaceutica
  • Johnson and Johnson
  • Nucleoside-Analog Reverse Transcriptase Inhibitors
  • NRTIs
  • Hospital
  • Clinics
  • Others

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Snapshot
          2.1.1. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market By Drug Class,2019
               2.1.1.1.Nucleoside-Analog Reverse Transcriptase Inhibitors
               2.1.1.2.NRTIs
          2.1.2. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market By Application,2019
               2.1.2.1.Hospital
               2.1.2.2.Clinics
               2.1.2.3.Others
          2.1.3. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market By End-use,2019
          2.1.4. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market By Geography,2019

3. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By Drug Class, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Drug Class, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Drug Class, 2020
     4.2. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By Drug Class, 2018 – 2028

5. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By Application, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Application, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Application, 2020
     5.2. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By Application, 2018 – 2028

6. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By End-use, 2018 – 2028

7. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis, 2018 – 2028 
          7.2.1. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By Drug Class, 2018 – 2028
          7.2.3. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By Application, 2018 – 2028
          7.2.4. North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis, 2018 – 2028 
          7.3.1.  Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By Drug Class, 2018 – 2028
          7.3.3. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By Application, 2018 – 2028
          7.3.4. Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By Drug Class, 2018 – 2028
          7.4.3. Asia Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By Application, 2018 – 2028
          7.4.4. Asia Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By Drug Class, 2018 – 2028
          7.5.3. Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By Application, 2018 – 2028
          7.5.4. Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis, 2018 – 2028 
          7.6.1.  MEA Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By Drug Class, 2018 – 2028
          7.6.3. MEA Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By Application, 2018 – 2028
          7.6.4. MEA Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Human Immunodeficiency Virus (HIV)-1 Therapeutics Providers
        8.4.1 Gilead Sciences, Inc
                8.4.1.1 Business Description
                8.4.1.2 Gilead Sciences, Inc Geographic Operations
                8.4.1.3 Gilead Sciences, Inc Financial Information
                8.4.1.4 Gilead Sciences, Inc Product Positions/Portfolio
                8.4.1.5 Gilead Sciences, Inc Key Developments
        8.4.2 ViiV Healthcare
                8.4.2.1 Business Description
                8.4.2.2 ViiV Healthcare Geographic Operations
                8.4.2.3 ViiV Healthcare Financial Information
                8.4.2.4 ViiV Healthcare Product Positions/Portfolio
                8.4.2.5 ViiV Healthcare Key Developments
        8.4.3 AbbVie, Inc
                8.4.3.1 Business Description
                8.4.3.2 AbbVie, Inc Geographic Operations
                8.4.3.3 AbbVie, Inc Financial Information
                8.4.3.4 AbbVie, Inc Product Positions/Portfolio
                8.4.3.5 AbbVie, Inc Key Developments
        8.4.4 Merck and Co., Inc
                8.4.4.1 Business Description
                8.4.4.2 Merck and Co., Inc Geographic Operations
                8.4.4.3 Merck and Co., Inc Financial Information
                8.4.4.4 Merck and Co., Inc Product Positions/Portfolio
                8.4.4.5 Merck and Co., Inc Key Developments
        8.4.5 Bristol-Myers Squibb Company
                8.4.5.1 Business Description
                8.4.5.2 Bristol-Myers Squibb Company Geographic Operations
                8.4.5.3 Bristol-Myers Squibb Company Financial Information
                8.4.5.4 Bristol-Myers Squibb Company Product Positions/Portfolio
                8.4.5.5 Bristol-Myers Squibb Company Key Developments
        8.4.6 Boehringer Ingelheim GmbH
                8.4.6.1 Business Description
                8.4.6.2 Boehringer Ingelheim GmbH Geographic Operations
                8.4.6.3 Boehringer Ingelheim GmbH Financial Information
                8.4.6.4 Boehringer Ingelheim GmbH Product Positions/Portfolio
                8.4.6.5 Boehringer Ingelheim GmbH Key Developments
        8.4.7 Genentech, Inc
                8.4.7.1 Business Description
                8.4.7.2 Genentech, Inc Geographic Operations
                8.4.7.3 Genentech, Inc Financial Information
                8.4.7.4 Genentech, Inc Product Positions/Portfolio
                8.4.7.5 Genentech, Inc Key Developments
        8.4.8 Cipla,Inc
                8.4.8.1 Business Description
                8.4.8.2 Cipla,Inc Geographic Operations
                8.4.8.3 Cipla,Inc Financial Information
                8.4.8.4 Cipla,Inc Product Positions/Portfolio
                8.4.8.5 Cipla,Inc Key Developments
        8.4.9 janssen Pharmaceutica
                8.4.9.1 Business Description
                8.4.9.2 janssen Pharmaceutica Geographic Operations
                8.4.9.3 janssen Pharmaceutica Financial Information
                8.4.9.4 janssen Pharmaceutica Product Positions/Portfolio
                8.4.9.5 janssen Pharmaceutica Key Developments
        8.4.10 Johnson and Johnson
                8.4.10.1 Business Description
                8.4.10.2 Johnson and Johnson Geographic Operations
                8.4.10.3 Johnson and Johnson Financial Information
                8.4.10.4 Johnson and Johnson Product Positions/Portfolio
                8.4.10.5 Johnson and Johnson Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue, By Drug Class, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue, By Drug Class, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue, By Drug Class, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue, By Drug Class, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue, By Drug Class, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics: Market Segmentation 
FIG. 2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, By Drug Class, 2019 (US$ Mn) 
FIG. 5 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, By Application, 2019 (US$ Mn) 
FIG. 6 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Human Immunodeficiency Virus (HIV)-1 Therapeutics Providers, 2019
FIG. 11 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue Contribution, By Drug Class, 2019 & 2028 (Value %) 
FIG. 12 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue Contribution, By Application, 2019 & 2028 (Value %) 
FIG. 13 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Human Immunodeficiency Virus (HIV)-1 Therapeutics market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, By Segment1, 2018 – 2028
TABLE  North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, By Segment2, 2018 – 2028
TABLE  North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, By Country, 2018 – 2028
TABLE  Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, By Segment1, 2018 – 2028
TABLE  Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, By Segment2, 2018 – 2028
TABLE  Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, By Country, 2018 – 2028
TABLE  Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, By Country, 2018 – 2028
TABLE  MEA Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, By Segment1, 2018 – 2028
TABLE  MEA Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, By Segment2, 2018 – 2028
TABLE  MEA Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, By Country, 2018 – 2028
TABLE  Gilead Sciences, Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  ViiV Healthcare: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  AbbVie, Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Merck and Co., Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Bristol-Myers Squibb Company: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Boehringer Ingelheim GmbH: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Genentech, Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Cipla,Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  janssen Pharmaceutica: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Johnson and Johnson: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, By Geography, 2019 (US$ Mn)
FIG.  Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Human Immunodeficiency Virus (HIV)-1 Therapeutics Providers, 2016
FIG.  Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global NRTIs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Clinics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Value, 2018 – 2028, (US$ Mn)